Accessibility Menu
Aequus Pharmaceuticals logo

Aequus Pharmaceuticals(OTC) AQSZF

Market Cap$159.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-99%
1 Year-40%
1 Month+9%
$0.00
-53.85%
-0.00Today
Aequus Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-29
Aequus Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-53.85%USD 0.002026-07-14
1 month+9.09%USD 0.002026-06-25
3 month+140%USD 0.002026-04-15
Year to date-40%USD 0.002025-12-22
1 year-40%USD 0.002025-07-29
3 year-96.55%USD 0.032023-07-28
5 year-98.83%USD 0.102021-07-30
Since inception-99.71%USD 0.412015-06-16

Aequus Pharmaceuticals Financials at a Glance

Market Cap

$159.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$918.47K

Net Income (TTM)

-CA$656.34K

EPS (TTM)

-$0.00

P/E Ratio

-0.35

Dividend

$0.00

Beta (Volatility)

-6.74 (Low)

Price

$0.00

Volume

20,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Jul 30, 2026

AQSZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, focused on developing and commercializing medicinal products. The company targets key medical areas, including neurological conditions, ophthalmology, and transplantation medicine.

Products and Services
  • Vistitan: An ophthalmic solution for open-angle glaucoma and ocular hypertension
  • Tacrolimus IR: An immunosuppressive drug for organ transplant management
  • Evolve range: Dry eye products for alleviating discomfort and dryness
Growth Outlook
  • Recent quarterly revenue increased to CAD 251,754, showing positive momentum
  • Strategic alliances with industry leaders enhance market reach and product promotion
  • Development pipeline includes innovative therapies for epilepsy and nausea during pregnancy
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 926,000 reflects growth potential
  • Net income for Q3 2025 was CAD 370,483, indicating improved profitability
  • Gross profit margin for Q3 2025 stood at 52.5%, showcasing operational efficiency
Aequus Pharmaceuticals Inc. operates in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic medications. The company has established a diverse product portfolio, including Vistitan, Tacrolimus IR, and the Evolve range of dry eye products. These offerings address significant medical needs, particularly in ophthalmology and transplantation. The growth outlook for Aequus is promising, with recent quarterly revenue showing an upward trend. Strategic partnerships with established companies in the pharmaceutical industry further bolster its market presence and product distribution capabilities. The ongoing development of innovative therapies, such as extended-release formulations for epilepsy and a transdermal patch for pregnancy-related nausea, positions Aequus for future growth. Financially, Aequus has demonstrated resilience, with a notable increase in revenue and a positive net income in the most recent quarter. The gross profit margin indicates effective cost management and operational efficiency. Overall, Aequus Pharmaceuticals Inc. presents a compelling opportunity for investors interested in the pharmaceutical sector, particularly in innovative and specialized medical solutions.
AI Generated • Jul 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

15

CEO

Douglas Glen Janzen

Website

www.aequuspharma.ca

Headquarters

Vancouver, BC V6C 1S4, CA

AQSZF Financials

Key Financial Metrics (TTM)

Gross Margin

53.98%

Operating Margin

-38.34%

Net Income Margin

-62.96%

Return on Equity

6.18%

Return on Capital

-1350.65%

Return on Assets

-223.56%

Earnings Yield

-2.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$159.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

132.63M

Volume

20.00K

Avg. Volume

40.76K

Financials (TTM)

Gross Profit

CA$523.04K

Operating Income

-CA$574.04K

EBITDA

-CA$348.26K

Operating Cash Flow

-CA$115.84K

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$115.84K

Cash & ST Invst.

CA$9.95K

Total Debt

CA$4.33M

Aequus Pharmaceuticals Performance Analysis

Aequus Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31CAD 2,165,293N/A
20222022-12-31CAD 1,059,852-51.1%
20232023-12-31CAD 188,856-82.2%
20242024-12-31CAD 426,462125.8%
Aequus Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3149.6%
Q12025-03-312.1%
Q22025-06-30-3.7%
Q32025-09-3015.4%
Aequus Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31CAD -0.01N/A
20222022-12-31CAD -0.0266.1%
20232023-12-31CAD -0.02-10.8%
20242024-12-31CAD -0.01-27.7%
Aequus Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3165.2%
Q12025-03-31-206.3%
Q22025-06-3075.5%
Q32025-09-30333.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

CA$251.75K

+69.7%

Gross Profit

CA$132.07K

+75.1%

Gross Margin

52.46%

N/A

Market Cap

$159.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$13.27K

N/A

Employees

12

N/A

Net Income

CA$370.48K

+160.3%

EBITDA

CA$308.31K

+160.0%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

CA$9.95K

-60.8%

Total Debt

CA$4.33M

-33.8%

Accounts Receivable

CA$165.75K

+154.1%

Inventory

CA$3.54K

-96.4%

Long Term Debt

CA$0.00

-100.0%

Short Term Debt

CA$4.33M

-28.4%

Return on Assets

-2.24%

N/A

Return on Invested Capital

3.87%

N/A

Free Cash Flow

-CA$21.22K

+93.9%

Operating Cash Flow

-CA$21.22K

+93.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HPMMHemp Naturals, Inc.
$0.00+0.00%
DVLPGolden Developing Solutions, Inc.
$0.00+0.00%
TOMDFTodos Medical Ltd.
$0.00+0.00%
BIOAFBioasis Technologies Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About AQSZF

What is the current price of Aequus Pharmaceuticals?

Aequus Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Aequus Pharmaceuticals?

Over the past 52 weeks, Aequus Pharmaceuticals has traded between $0.00 and $0.01.

How much debt does Aequus Pharmaceuticals have?

As of the most recent reporting period, Aequus Pharmaceuticals reported total debt of CA$4.33M.

How much cash does Aequus Pharmaceuticals have on hand?

Aequus Pharmaceuticals reported CA$9.96K in cash and cash equivalents in its most recent financial results.

What is Aequus Pharmaceuticals’s dividend yield?

Aequus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services